Literature DB >> 7720169

Delivery and cytotoxicity of RS-1541 in St-4 human gastric cancer cells in vitro by the low-density-lipoprotein pathway.

T Tokui1, T Takatori, N Shinozaki, M Ishigami, A Shiraishi, T Ikeda, T Tsuruo.   

Abstract

RS-1541 is a 13-O-palmitoyl derivative of rhizoxin, an inhibitor of tubulin polymerization. RS-1541 has been shown to bind preferentially to plasma lipoproteins and to exhibit selective and sustained uptake by tumors in mice. To elucidate a mechanism of RS-1541 cytotoxicity, the cellular uptake and the cytotoxicity of a complex of RS-1541 with human low-density lipoprotein (RS-1541/LDL complex) were investigated in cultured St-4 human gastric cancer cells. Both the cellular uptake and the cytotoxicity of the RS-1541/LDL complex were greater in cells with higher LDL-receptor activities than in control cells. Excess amounts of LDL or 1 microM of monensin, a proton ionophore, significantly inhibited both the uptake and the cytotoxicity of the complex. Chloroquine, an inhibitor of lysosomal enzymes, decreased the intracellular level of rhizoxin liberated from RS-1541 and suppressed the cytotoxicity of the RS-1541/LDL complex. However, a detergent-aided solution of RS-1541 showed very low cellular uptake and cytotoxicity, irrespective of the LDL-receptor activities of these cells. These results demonstrate that the RS-1541/LDL complex is incorporated into the cells via the LDL receptor and that it manifests its cytotoxic activity after forming rhizoxin, the original antitumor agent, in the lysosomes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720169     DOI: 10.1007/BF00685724

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations.

Authors:  D W Bilheimer; S Eisenberg; R I Levy
Journal:  Biochim Biophys Acta       Date:  1972-02-21

Review 2.  Lipoprotein-polyanion-metal interactions.

Authors:  M Burstein; H R Scholnick
Journal:  Adv Lipid Res       Date:  1973

3.  Studies on macrocyclic lactone antibiotics. VII. Structure of a phytotoxin "rhizoxin" produced by Rhizopus chinensis.

Authors:  S Iwasaki; H Kobayashi; J Furukawa; M Namikoshi; S Okuda; Z Sato; I Matsuda; T Noda
Journal:  J Antibiot (Tokyo)       Date:  1984-04       Impact factor: 2.649

4.  Assimilation of LDL by experimental tumours in mice.

Authors:  P Lombardi; G Norata; F M Maggi; G Canti; P Franco; A Nicolin; A L Catapano
Journal:  Biochim Biophys Acta       Date:  1989-06-28

5.  In vivo assimilation of low density lipoproteins by a fibrosarcoma tumour line in mice.

Authors:  G Norata; G Canti; L Ricci; A Nicolin; E Trezzi; A L Catapano
Journal:  Cancer Lett       Date:  1984-12       Impact factor: 8.679

6.  Elevated uptake of low density lipoproteins by human lung cancer tissue in vivo.

Authors:  S Vitols; C Peterson; O Larsson; P Holm; B Aberg
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

7.  Contribution of serum lipoproteins as carriers of antitumour agent RS-1541 (palmitoyl rhizoxin) in mice.

Authors:  T Tokui; C Kuroiwa; Y Tokui; K Sasagawa; K Kawai; T Kobayashi; T Ikeda; T Komai
Journal:  Biopharm Drug Dispos       Date:  1994-03       Impact factor: 1.627

8.  Studies on macrocyclic lactone antibiotics. XI. Anti-mitotic and anti-tubulin activity of new antitumor antibiotics, rhizoxin and its homologues.

Authors:  M Takahashi; S Iwasaki; H Kobayashi; S Okuda; T Murai; Y Sato; T Haraguchi-Hiraoka; H Nagano
Journal:  J Antibiot (Tokyo)       Date:  1987-01       Impact factor: 2.649

9.  Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms.

Authors:  D Gal; M Ohashi; P C MacDonald; H J Buchsbaum; E R Simpson
Journal:  Am J Obstet Gynecol       Date:  1981-04-15       Impact factor: 8.661

10.  Low density lipoprotein for delivery of a water-insoluble alkylating agent to malignant cells. In vitro and in vivo studies of a drug-lipoprotein complex.

Authors:  S Vitols; K Söderberg-Reid; M Masquelier; B Sjöström; C Peterson
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

View more
  3 in total

1.  Tumor selective effect of RS-1541 (palmitoyl-rhizoxin) in M5076 sarcoma and host tissues in vivo.

Authors:  T Tokui; N Maeda; C Kuroiwa; K Sasagawa; T Inoue; K Kawai; T Ikeda; T Komai
Journal:  Pharm Res       Date:  1995-03       Impact factor: 4.200

Review 2.  Influence of liver cancer on lipid and lipoprotein metabolism.

Authors:  Jingting Jiang; Peter Nilsson-Ehle; Ning Xu
Journal:  Lipids Health Dis       Date:  2006-03-03       Impact factor: 3.876

3.  Potential antitumor activity of novel DODAC/PHO-S liposomes.

Authors:  Arthur Cássio de Lima Luna; Greice Kelle Viegas Saraiva; Otaviano Mendonça Ribeiro Filho; Gilberto Orivaldo Chierice; Salvador Claro Neto; Iolanda Midea Cuccovia; Durvanei Augusto Maria
Journal:  Int J Nanomedicine       Date:  2016-04-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.